医学
克拉斯
肺癌
癌症研究
癌症
靶向治疗
肿瘤科
内科学
结直肠癌
作者
Garo Hagopian,Christopher H. Grant,Misako Nagasaka
标识
DOI:10.1016/j.ctrv.2023.102561
摘要
Non-small cell lung cancer (NSCLC) has very poor prognosis in advanced stages. Discovery and application of therapies targeting specific oncogenic driver mutations has greatly improved overall survival. However, targeted therapies are limited in their efficacy due to resistance mutations that may arise with long term use. Proteolysis targeting Chimeras (PROTACs) are a promising approach to combating resistance mutations. PROTACs commandeer innate ubiquitination machinery to degrade oncogenic proteins. Here we review the PROTACs that have been developed for targeting common EGFR, KRAS, and ALK mutations.
科研通智能强力驱动
Strongly Powered by AbleSci AI